An experimental drug developed ​by China-based Akeso helped patients with advanced squamous non-small cell lung cancer live 15% longer than BeOne Medicines' immunotherapy Tevimbra, ‌and cut the risk of death by more than one-third in a study presented at a medical meeting on Sunday.